Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy

Background: Nusinersen is an intrathecally administered antisense oligonucleotide (ASO) and the first approved drug for the treatment of spinal muscular atrophy (SMA). However, progressive neuromyopathic scoliosis and the presence of spondylodesis can impede lumbar punctures in SMA patients. Our aim was to assess the feasibility and safety of the treatment in adults with SMA. Methods: For the intrathecal administration of nusinersen, we performed conventional, fluoroscopy-assisted and computer tomography (CT)-guided lumbar punctures in adult patients with type 2 and type 3 SMA. We documented any reported adverse events and performed blood tests. Results: We treated a total of 28 adult SMA patients (9 patients with SMA type 2 and 19 patients with SMA type 3) aged between 18–61 years with nusinersen. The mean Revised Upper Limb Module (RULM) score at baseline in SMA type 2 and SMA type 3 patients was 9.9 ± 4.6 and 29.5 ± 8.5, respectively. The mean Hammersmith Functional Motor Scale Expanded (HFMSE) score at baseline was 3.1 ± 2.5 and 31.2 ± 18.1, respectively. Half of the SMA type 3 patients were ambulatory at treatment onset. In total, we performed 122 lumbar punctures with 120 successful intrathecal administrations of nusinersen. Lumbar punctures were well tolerated, and no serious adverse events occurred. Conclusions: Our data demonstrate the feasibility and tolerability of intrathecal treatment with nusinersen in adults with SMA type 2 and type 3. However, treatment can be medically and logistically challenging, particularly in patients with SMA type 2 and in patients with spondylodesis.

[1]  S. Bhalla,et al.  Use of Ommaya Reservoir with a Thoracic Spinal Catheter for Intrathecal Delivery of Nusinersen in a Patient with Spinal Muscular Atrophy Type 2 (P4.464) , 2018 .

[2]  P. Westesson,et al.  Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy , 2018, Neurology.

[3]  R. Finkel,et al.  Nusinersen versus Sham Control in Later‐Onset Spinal Muscular Atrophy , 2018, The New England journal of medicine.

[4]  Ewout J. N. Groen,et al.  Overview of Current Drugs and Molecules in Development for Spinal Muscular Atrophy Therapy , 2018, Drugs.

[5]  R. Finkel,et al.  Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics , 2017, Neuromuscular Disorders.

[6]  W. Chung,et al.  Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care , 2017, Neuromuscular Disorders.

[7]  R. J. Ramamurthi,et al.  Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.

[8]  Bernhard Hemmer,et al.  Consensus guidelines for lumbar puncture in patients with neurological diseases , 2017, Alzheimer's & dementia.

[9]  Manfred Westphal,et al.  Intracerebroventricular Delivery as a Safe, Long-Term Route of Drug Administration. , 2017, Pediatric neurology.

[10]  M. Han,et al.  Patient Radiation Exposure During Diagnostic and Therapeutic Procedures for Intracranial Aneurysms: A Multicenter Study , 2016, Neurointervention.

[11]  H. Wong,et al.  Long-term Follow-up of Pulmonary Function and Scoliosis in Patients With Duchenne’s Muscular Dystrophy and Spinal Muscular Atrophy , 2015, Journal of pediatric orthopedics.

[12]  M. Choy.  Pharmaceutical Approval Update. , 2016, P & T : a peer-reviewed journal for formulary management.

[13]  E. Bertini,et al.  Orthopedic Management of Scoliosis by Garches Brace and Spinal Fusion in SMA Type 2 Children , 2015, Journal of neuromuscular diseases.

[14]  E. Bertini,et al.  Childhood spinal muscular atrophy: controversies and challenges , 2012, The Lancet Neurology.

[15]  N. Nagan,et al.  Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimens , 2011, European Journal of Human Genetics.

[16]  Y. Hua,et al.  Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy , 2011, Science Translational Medicine.

[17]  Rebecca S Lewis,et al.  Projected cancer risks from computed tomographic scans performed in the United States in 2007. , 2009, Archives of internal medicine.

[18]  Mitchell R Lunn,et al.  Spinal muscular atrophy , 2008, The Lancet.

[19]  G. Levy,et al.  The changing natural history of spinal muscular atrophy type 1 , 2007, Neurology.

[20]  T. Wienker,et al.  Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. , 2002, American journal of human genetics.

[21]  A. Levin,et al.  Pharmacokinetics of phosphorothioate antisense oligodeoxynucleotides. , 2001, Current opinion in investigational drugs.

[22]  C. Lorson,et al.  An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. , 2000, Human molecular genetics.

[23]  C. Lorson,et al.  A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Vilming,et al.  Pain Location and Associated Symptoms in Post-Lumbar Puncture Headache , 1998, Cephalalgia : an international journal of headache.

[25]  Arnold Munnich,et al.  Correlation between severity and SMN protein level in spinal muscular atrophy , 1997, Nature Genetics.

[26]  K. Zerres,et al.  A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients , 1997, Journal of the Neurological Sciences.

[27]  A. Munnich,et al.  Structure and organization of the human survival motor neurone (SMN) gene. , 1996, Genomics.

[28]  J. Weissenbach,et al.  Identification and characterization of a spinal muscular atrophy-determining gene , 1995, Cell.

[29]  T. Munsat,et al.  International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany) , 1992, Neuromuscular Disorders.

[30]  T. Munsat.  International SMA consortium meeting , 1992 .